Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP). At some tissues, RBP is recognized by STRA6, a plasma membrane protein that serves a dual role: it transports retinol from extracellular RBP into cells and it transduces a signaling cascade mediated by the Janus kinase JAK2 and the transcription factors STAT3 and STAT5. We show here that expression of RBP and STRA6 is markedly upregulated in human breast and colon tumors, that holo-RBP/STRA6 signaling promotes oncogenic properties, and that STRA6 expression is critical for tumor formation by colon carcinoma cells in vivo. The holo-RBP/STRA6 pathway also efficiently induces fibroblasts to undergo oncogenic transformation, rendering them highly tumorigenic. These data establish that holo-RBP and its receptor STRA6 are potent oncogenes and suggest that the pathway is a novel target for therapy of some human cancers. Cancer Res; 74(21); 1-11. Ó2014 AACR.
Introduction
Vitamin A, retinol (ROH), is essential for multiple biologic functions both during embryonic development and in the adult. Many of the biologic activities of retinol are exerted by its active metabolite all-trans-retinoic acid (RA), which regulates transcription by activating the nuclear receptors retinoic acid receptors and PPARb/d (1, 2) . Vitamin A is stored in various tissues, including adipose tissue, lung, and retinal pigment epithelium in the eye, but its major storage site is in the liver. ROH is secreted from storage pools into the circulation bound to serum retinol-binding protein (RBP). In turn, ROH-bound RBP (holo-RBP) associates in blood with another plasma protein, transthyretin (TTR), to form a holo-RBP-TTR complex that circulates at approximately 1:1 molar stoichiometry under normal physiologic conditions (3, 4) .
ROH enters target cells from circulating holo-RBP by two distinct mechanisms. Because of its lipophilic nature, it readily diffuses through the plasma membrane, a process that, in most tissues, accounts for the major fraction of vitamin A uptake by cells (4) (5) (6) (7) . ROH can also be transported into cells by an integral plasma membrane protein termed Stimulated by RA 6 (STRA6), which binds extracellular holo-RBP and transports ROH into cells (8) . Although STRA6-mediated ROH uptake is not necessary for maintaining adequate ROH supply in most tissues, its contribution to ROH supply becomes significant in cells that express a very high level of the receptor, primarily the retinal pigment epithelium (RPE) in the eye (7, 9) .
Our recent studies surprisingly revealed that, in addition to serving as a vitamin A transporter, STRA6 is a cytokine receptor. We thus found that binding of holo-RBP triggers phosphorylation of a tyrosine residue in the cytosolic domain of STRA6, resulting in recruitment and activation of the Janus kinase JAK2 and, in a cell-dependent manner, the transcription factors STAT3 or STAT5 (10, 11) . Holo-RBP thus activates STRA6-mediated signaling that culminates in upregulation of STAT target genes. Interestingly, the two functions of STRA6 were found to be interdependent, i.e., STRA6-mediated ROH transport is required for activation of STRA6 signaling, and, vice versa, phosphorylation of STRA6 is essential for retinol transport mediated by the receptor (11) . The observations further demonstrated that STRA6 directly transfers ROH from extracellular RBP to cellular retinol-binding protein 1 (CRBP1), which directly binds to STRA6, accepts ROH, and dissociates from the receptor upon ligation (11) . STRA6-mediated ROH uptake also critically requires the presence of lecithin:retinol acyl transferase (LRAT), an enzyme that catalyzes the conversion of retinol to its storage species retinylesters. Transfer of ROH from CRBP1 to LRAT regenerates apo-CRBP1, enabling the binding protein to reassociate with STRA6 and further promote ROH uptake and STRA6 signaling (11) . ROH metabolism by LRAT also maintains an inward directed ROH concentration gradient, necessary for continuing influx. Hence, STRA6 orchestrates a multicomponent "machinery" that couples vitamin A homeostasis and metabolism to activation of a signaling cascade.
Importantly, the binding partner for RBP in blood, TTR, competes with STRA6 for holo-RBP and thus prevents holo-RBP from interacting with the receptor. Consequently, STRA6 is only active either when holo-RBP levels in serum exceed that of TTR, e.g., in obese animals (5, 12, 13) , or in cells that express a very high level of the receptor, e.g., the RPE. Other physiologic circumstances that enable STRA6 signaling remain to be identified, but it has been reported that STRA6 is upregulated in several human cancers, including Wilm kidney tumors, melanomas, and colorectal, ovarian, and endometrium cancers (14) . The functional significance of the increased expression of STRA6 in carcinoma cells is unknown, but the discovery that STRA6 signaling triggered by holo-RBP activates a JAK2/ STAT3/5 cascade may provide a clue. These STATs are associated with inflammation, cellular transformation, survival, proliferation, invasion, and angiogenesis, and they are considered to be oncogenes (15) (16) (17) (18) . Tumor-promoting STAT target genes include the cell-cycle regulators cyclin D1 and cyclin D3, the oncogene c-Myc, the growth factor VEGF, genes involved in migration and invasion such as MMP-9, and antiapoptotic genes including survivin, Mcl-1, and Bcl-XL (16, 19) . Hence, an intriguing possibility is that STRA6 and its associated machinery may be involved in oncogenic activities. Work described in this article aimed to examine this possibility.
Materials and Methods

Reagents
The antibodies STAT3, pSTAT3, and PCNA were obtained from Cell Signaling Technology; actin and histidine were obtained from Santa Cruz; STRA6 from Novus Biologicals; and for STRA6 polyclonal antibody (see ref. 7) . Expression vector for his-STRA6 was from Genecopia. Mutants were generated using a QuikChange mutagenesis kit (Stratagene). Breast (BCRT101) and colon (HC105) cancer arrays were purchased from OriGene. RBP4shRNAs were from Open Biosystems (TRCN0000060040) or Sigma (TRCN0000060038 and TRCN0000060042). STRA6shR-NAs (TRCN0000128799 and TRCN0000129158) were obtained from Open Biosystems. AG490 and ROH were from Calbiochem and Sigma Chemical Co., respectively. Transfections were carried out using PolyFact (Qiagen).
RBP was expressed in E. coli and purified as described in ref. 20 . The preparation typically yields holo-RBP at an ROH: RBP mole ratio of 0.8:1.0.
Cells
HCT116, SW480, and SW620 cells were purchased from the ATCC and cultured in McCoy's 5A media supplemented with 10% FBS. NIH3T3 fibroblasts were purchased from the ATCC and cultured in DMEM supplemented with FBS. Generation of NIH3T3 fibroblasts stably overexpressing LRAT was previously described (21) . Generation of HCT116 cells expressing the Y705F dominant-negative mutant of STAT3 was previously described (22) . HCT116 cells stably overexpressing STRA6 were generated by transfection of vector encoding his-STRA6 and selection using G418 (10 mg/mL). Colonies were pooled. SW480 stable lines with reduced expression of STRA6 or RBP were generated using lentiviral vectors pLKO.1-puro encoding respective shRNA targeting GFP, human STRA6 (Open Biosystems), or human RBP (Sigma). Viruses were packaged in HEK293T cells and used as per the manufacturer's protocols. Cells were selected using 10 mg/mL puromycin. NIH3T3-L1 cells were differentiated as previously described (23) .
A BrdUrd proliferation assay kit was purchased from EMD Millipore.
Quantitative real-time PCR
RNA was extracted using TriZol. cDNA was generated using GeneAmp RNA PCR (Applied Biosystems). Quantitative real-time PCR (qRT-PCR) was carried out using TaqMan chemistry and Assays-on-Demand probes (Applied Biosystems): MMP9 (Hs00957562_m1), MYC (Hs99999003_m1), STRA6 (Hs00980261_g1), VEGFA (Hs00900055_m1), C-FOS (Hs00170630_m1), CCND1 (Hs00765553_m1), and 18s (4352930) rRNA.
Soft agar assays
Agar (0.8%) was placed in a 6-well plate, allowed to solidify, and topped with 2,500 cells/mL in 0.3% agar and growth media. Agar media (0.3%) were replaced every 48 hours for 21 days, and colonies were visualized using 0.5% crystal violet.
Migration assays were performed using 8-mm pore size Transwell migration plates (Corning) plated with 10 4 cells/cm 2 of HCT116 and NIH3T3 fibroblasts and 10 5 cells/cm 2 of SW480 cells. Cells were placed on the bottom of the Transwell plate at 100% confluence. Cells in the top chamber were allowed to migrate for 12 hours, the top portion of the insert was wiped with a cotton swab, inserts were fixed in 4% formalin (30 minutes), and washed twice with PBS. Cells were stained with 0.5% crystal violet (10-15 minutes), washed twice with PBS, visualized, and counted.
Wound-healing assays
Cells were grown in growth media to 100% confluence and scratched using a 200-mL pipette tip. Cells were washed extensively with PBS to remove floating cells, and images were taken at initial, 12 hours, and 24 hours after scratching. Similar results were obtained using Ibidi wound-healing chambers.
Invasion assays were performed using BD bioscience invasion assay following the manufacture's protocol.
Secondary focus formation assays
NIH3T3 fibroblasts (10,000) and 1,000 HCT116 or SW480 cells were plated. Media were replaced every 48 hours for 14 days. Media were removed, and cells were washed with PBS, fixed in 10% formalin, and stained for 30 minutes in 0.5% crystal violet.
Immunoblots
Cell protein was extracted using RIPA buffer (25 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS). Proteins were resolved by SDS-PAGE, transferred onto nitrocellulose membrane, and immunoblotted. Band intensities were quantified using the ImageJ 1.40g software (Wayen Rasband) .
Mice
NCr athymic mice were housed in accordance with ARC protocol and Institutional Animal Care and Use Committee regulations. Six-week-old male athymic mice were subcutaneously injected with 2 Â 10 6 HCT116, 5 Â 10 6 SW480, or 5 Â 10 6 NIH3T3 cells. Tumors were measured using calipers, and tumor volume was calculated by (length Â width 2 /2).
Database analysis
Normalized data from Oncomine Cancer Microarray database were plotted as a log median change and SD determined for each independent array.
Statistical analysis
Statistical significance of treatments was analyzed using an independent sample t test.
Results
Expression of STRA6 and RBP is upregulated in breast and colon cancers
Expression array profiles deposited in the database Oncomine (Compedia Bioscience) indicate that three independent studies documented that the level of STRA6 mRNA is elevated in human breast tumors versus normal breast tissue (Fig. 1A and Supplementary Fig. S1A and S1B) . Accordingly, analysis of a human breast cancer cDNA array (OriGene) showed that STRA6 expression is significantly higher in breast tumors as compared with normal mammary tissue (Fig. 1B) . These data showed marked variability and, likely due to the small number of samples on the array, the increase was not statistically significant in all stages. However, a clear trend indicating that STRA6 was upregulated early during tumor development was seen, and it reached statistical significance in stages I, IIB, and IV (Fig. 1B) . STRA6 expression was higher in mammary carcinoma MCF-7 and MBA-MD-231 cells than in normal breast epithelium (HuMEC) cells (Fig. 1C) . Similarly, STRA6 was undetectable in normal colon and significantly elevated in colon carcinoma ( Fig. 1D and Supplementary Fig. S1C and S1D ). Analysis of a human colon cancer cDNA array further suggested that the level of STRA6 increases progressively along with tumor development (Fig. 1E) . STRA6 was also found to be upregulated during polyp formation in APC min mouse model of colon adenoma (Fig. 1F ), and correlated with the tumorigenic potential of human colon cancer cell lines (Fig. 1G) . The level of RBP, the STRA6 ligand, was also elevated in MCF-7 and MBA-MD-231 mammary carcinoma cells (Fig. 1H) , and was associated with the metastatic potential of the 67NR series of isogenic breast cancer cell lines (ref. 24; Supplementary Fig. S1E ). RBP expression was higher in human colon tumors versus normal colon ( Fig. 1I and Supplementary Fig. S1F and S1G), and, similarly to STRA6, analysis of a cDNA array suggested that RBP levels increase progressively with colon cancer development (Fig. 1J) . Also similarly to STRA6, RBP expression was found to be associated with the aggressiveness of human colon cancer cell lines (Fig. 1K ).
RBP and STRA6 facilitate carcinoma cell proliferation
HCT116 colon carcinoma cells, which express low levels of STRA6 and RBP, and SW480 and the highly metastatic SW620 colon carcinoma cell lines, which highly express both proteins ( Fig. 2A and B) , were used to begin to examine the role of RBP and STRA6 in tumor development. An HCT116 cell line that stably overexpresses STRA6 was generated (Fig. 2C ). Treatment of HCT116 cells with holo-RBP or overexpression of STRA6 modestly facilitated their growth, but combining the two factors by treating STRA6-overexpressing cells with holo-RBP markedly enhanced proliferation (Fig. 2C) . In accordance, treatment of STRA6-overexpressing cells with holo-RBP enhanced DNA synthesis, reflected by BrdUrd incorporation, by almost 2-fold (Fig. 2D) . In contrast, expression of the signaling-defective mutant STRA6-Y643F abolished the ability of holo-RBP to induce DNA synthesis (Fig. 2D) . We also generated SW480 cell lines in which STRA6 expression was stably decreased by two independent lentiviral vectors encoding STRA6shRNAs and which displayed 40% and 80% reduction in receptor expression, respectively ( Supplementary Fig. S2A , inset). The decrease in STRA6 expression suppressed DNA synthesis in a dose-dependent manner ( Supplementary Fig.  S2A ). A third SW480 cell line, which stably expresses both constructs, was then generated. Treatment of these cells with holo-RBP markedly facilitated their proliferation, and reducing STRA6 expression inhibited growth and hampered the proproliferative activity of holo-RBP (Fig. 2E) . Accordingly, reducing the expression of STRA6 suppressed DNA synthesis and abolished the ability of holo-RBP to enhance BrdUrd incorporation (Fig. 2F ). Ectopic expression of bSTRA6 rescued holo-RBP-induced DNA synthesis in cells with reduced expression of the endogenous hSTRA6 (Fig. 2F ). STRA6 and holo-RBP also cooperated in promoting DNA synthesis and proliferation in MCF-7 mammary carcinoma cells (Supplementary Fig. S2B and S2C) and promoted BrdUrd incorporation in SW620 colon carcinoma cells ( Supplementary Fig. S2E ). Similarly, reducing the expression of RBP in SW480 cells suppressed DNA synthesis and did so in a dose-dependent manner (Fig. 2G ). Although holo-RBP induced proliferation of SW480 cells, neither ROH alone nor RA exerted such an activity (Fig. 2H ), demonstrating that holo-RBP exerts pro-proliferative activities independently from generation of ROH-derived RA.
RBP and STRA6 promote oncogenic properties
HCT116 and SW480 cells were also used to investigate the effects of RBP and STRA6 on various hallmarks of oncogenic transformation. Parental HCT116 cells, which express a low level of STRA6, showed minimal activity in secondary focus formation assays (Fig. 3A) . Overexpression of STRA6 markedly enhanced the ability of these cells to form foci, and holo-RBP further potentiated the activity (Fig. 3A) . Overexpression of STRA6 and holo-RBP also facilitated the rate of migration of HCT116 cells (Fig. 3B ) and their invasion through matrix gel (Fig. 3C ). In accordance, STRA6-overexpressing HCT116 cells displayed facilitated wound closure behavior in scratch assays ( Fig. 3D; Supplementary Fig. S2G ). Overexpression of STRA6 markedly increased both the number and the size of colonies formed by HCT116 cells in soft agar ( Fig. 3E and Supplementary Fig. S2H ). In SW480 cells, holo-RBP promoted foci formation ( Fig. 3F ) and facilitated cell migration ( Fig. 3G ) and invasion ( Fig. 3H) . Strikingly, decreasing the expression of STRA6 in SW480 cells completely abolished these responses ( Fig. 3F-H) . The reduced expression of STRA6 also hampered the wound closure behavior of the cells (Fig. 3I ) and the number and diameter of colonies formed in soft agar ( Fig. 3J and Supplementary Fig. S2I ). STRA6 and holo-RBP also promoted oncogenic activities in MCF-7 mammary carcinoma cells (Supplementary Fig. S2D ) and in SW620 colon cancer cells ( Supplementary Fig. S2E and S2F) .
The observations that, in addition to STRA6, SW480 cells also express a high level of RBP (Fig. 2B ) raise the question of whether RBP functions by activating STRA6 following its secretion from the cells or whether it has intracellular activities. SW480 cells and counterparts expressing reduced level of RBP ( Supplementary Fig. S3A ) were cultured in serum-free medium for 24 hours, and conditioned media were collected. Media were placed on parental SW480 cells, and scratch assays were carried out. Conditioned media from parental SW480 cells efficiently promoted wound healing, whereas media from cells with reduced expression of RBP did not (Fig. 3K) . Similarly, SW480 cells cultured in conditioned media from cultured adipocytes displayed a more efficient wound closure behavior as compared with cells treated with media from adipocytes with reduced RBP expression ( Supplementary Fig. S3B and S3C). The ability of secreted RBP to promote the motility of neighboring cells was then examined by coculture experiments. SW480 cells that overexpress RBP (Supplementary Fig.  S3D ) or express RBPshRNA were plated at the bottom of a Transwell plate. SW480 cells that express an empty vector or a vector encoding STRA6shRNA were plated at the top of the Transwell plate, and their migration toward the bottom was assessed 12 hours later. Overexpression of RBP in cells in the lower chamber facilitated, and downregulation of RBP inhibited, the movement of cells from the top chamber. This activity of RBP was found to critically require expression of STRA6 (Fig.  3L) . Notably, as STRA6 is activated by holo-and not apo-RBP (5, 10), these observations indicate that RBP was secreted from cells in complex with retinol. The observations thus demonstrate that holo-RBP can signal in a paracrine fashion. Oncogenic activities of RBP and STRA6 are mediated by STAT3 Treatment with holo-RBP increased the phosphorylation level of STAT3 both in HCT116 colon cancer cells (Fig. 4A ) and in MCF-7 mammary carcinoma cells (Supplementary Fig. S3E ). Holo-RBP also induced STAT3 phosphorylation in SW480 cells, and the effect was lost upon downregulation of STRA6 (Fig. 4B) . Attesting to activation of STAT, holo-RBP induced the expression of several pro-oncogenic STAT target genes, including c-Fos, cyclin D1, VEGF-A, and MMP9 in HCT116 (Fig. 4C ) and in SW480 cells (Fig. 4D) . This activity was augmented upon overexpression of STRA6 in HCT116 cells (Fig. 4C) and suppressed upon decreasing STRA6 expression or ectopic expression of a signaling-defective STRA6 mutant in SW480 cells ( Fig. 4D and Supplementary Fig. S4A ). Expression of these genes decreased in a dose-dependent fashion upon reducing the expression of either STRA6 ( Supplementary Fig. S4B ) or RBP ( Supplementary Fig. S4C ). Induction of these genes by holo-RBP was not inhibited by pretreatment with the protein synthesis inhibitor cycloheximide, demonstrating that it was exerted by direct transcriptional control ( Supplementary Fig.  S4D ). Treatment of SW480 cells with the JAK inhibitor AG490 suppressed holo-RBP-induced upregulation of the genes (Fig.  4E) . In HCT116 cells, stable overexpression of a dominantnegative construct of STAT3 (STAT3-Y705F, STAT3-DN; ref. 25) prevented holo-RBP-induced STAT3 phosphorylation (Fig.  4F) , and it abolished the ability of holo-RBP to upregulate the expression of c-Fos (Fig. 4G) and to enhance BrdUrd incorporation (Fig. 4H) . Decreasing the expression of STAT3 (Supplementary Fig. S4E ) abolished the ability of holo-RBP to induce cFos (Fig. 4I ) and to facilitate cell migration (Fig. 4J) . Hence, holo-RBP and STRA6 promote proliferation and migration of these cells by activating STAT3.
STRA6 is critical for colon tumor development in a xenograft mouse model NCr athymic mice were used to explore the involvement of STRA6 in colon tumor formation in vivo. To minimize variability between animals, each mouse was injected with the parental HCT116 cells into one flank and HCT116 cells that stably overexpress STRA6 into the opposite flank. Sites injected with cells that overexpress STRA6 developed markedly larger tumors than sites injected with parental cells (Fig. 5A) . Immunostaining showed that STRA6-overexpressing neoplasm expressed higher levels of the proliferation marker Ki67 (Fig. 5B ) and the DNA synthesis marker PCNA (Fig. 5C) . The phosphorylation status of STAT3 was higher in STRA6-overexpressing tumors (Fig. 5C ) and, accordingly, these tumors expressed higher levels of c-Fos, VEGF-A, cyclin D1, and MMP9 (Fig. 5D) .
SW480 cells were used to further examine whether STRA6 is critical for tumor development. NCr athymic mice were injected with SW480 cells into the right flank, and SW480 cells in which STRA6 expression is stably downregulated into the left flank. Tumor development was markedly suppressed by reducing the expression of STRA6 (Fig. 5E) . Phosphorylation of STAT3 (Fig. 5F ) and expression of prooncogenic STAT target genes (Fig. 5G) were both markedly lower in tumors that arose from cells with reduced expression of STRA6.
STRA6 and its associated machinery induce oncogenic transformation in NIH3T3 fibroblasts
The ability of STRA6 signaling to transform NIH3T3 fibroblasts, a classical approach for examining the oncogenic potential of proteins, was then examined. STRA6 signaling is coupled to cellular uptake of retinol, and both activities require the expression of the intracellular retinol acceptor CRBP1 and the retinol-metabolizing enzyme LRAT (11). NIH3T3 cells express CRBP1 but not STRA6 or LRAT (5, 11) . To examine whether the entire STRA6-associated machinery is necessary for oncogenic activities, NIH3T3 cells that stably express STRA6 or stably coexpress STRA6 and LRAT were generated. As a control, an additional cell line that stably coexpresses LRAT and the signaling-defective STRA6-T644M mutant was also generated (Fig 6A, inset) .
Overexpression of either LRAT or STRA6 alone did not affect NIH3T3 cell growth, but coexpression of the receptor and the enzyme significantly facilitated proliferation (Fig.  6A ) and potentiated the ability of holo-RBP to promote DNA synthesis (Fig. 6B) . Coexpression of STRA6 and LRAT also increased the phosphorylation status of STAT3 (Fig. 6C) , upregulated the expression of oncogenic STAT target genes ( Fig. 6D) , facilitated closure in scratch assays (Fig. 6E) , and enhanced cell migration (Fig. 6F) . LRAT-and STRA6-expressing cells, but not cells expressing STRA6 alone or LRAT in conjunction of the signaling-defective STRA6-T644M mutant, formed colonies in soft agar (Fig. 6G) . Finally, when injected into athymic mice, NIH3T3 cells that coexpress LRAT and STRA6 efficiently developed tumors resembling fibrosarcoma (Fig. 6H) . Although tumors developed in 5 of 10 animals injected with cells coexpressing LRAT and STRA6, no tumors arose in any site injected with cells expressing LRAT in conjunction with STRA6-T644M (Fig. 6I) . Hence, STRA6 and its associated machinery potently promote oncogenic transformation.
Discussion
The observations demonstrate that RBP and its plasma membrane receptor STRA6 are undetectable in normal colon and mammary epithelium and are upregulated in some breast and colon cancers. The signals that induce the expression of these genes remain to be investigated, but the data suggest that STRA6 is upregulated early in breast cancer development and that expression of both the receptor and its ligand RBP progressively increases throughout colon cancer progression.
As shown in Fig. 7 , the data show that RBP is secreted from carcinoma cells and activates STRA6, which, in turn, triggers JAK2/STAT3 signaling, resulting in induction of multiple prooncogenic STAT target genes. Hyperactivation of STRA6 may thus underlie the well-documented observations that STAT3 is constitutively active in multiple cancers (26) . In accordance with the observations that STRA6 signaling is coupled to retinol metabolism (11), oncogenic activities of STRA6 require the expression of the retinol-esterifying enzyme LRAT. STRA6 thus links retinol uptake and intracellular metabolism to activation of a JAK/STAT cascade and promotion of oncogenic transformation. In contrast with these conclusions, it was recently reported that STRA6 contributes to p53-induced apoptosis in response to DNA damage (27) . The basis for the discrepancy and the mechanism through which STRA6 may exert a proapoptotic activity remains to be clarified. Considering that holo-RBP circulates in blood at 1 to 2 mmol/L concentrations, mechanisms that protect tissues from hyperactivation of STRA6 must exist. One such mechanism is the association of holo-RBP with its serum-binding partner TTR, which efficiently competes with STRA6 for holo-RBP and thus inhibits STRA6-initiated cell signaling (5) . It could thus be expected that animals would be protected from the oncogenic activities of the pathway when serum holo-RBP level does not exceed that of TTR. Moreover, due to its low molecular weight, free holo-RBP is rapidly excreted by glomeruli filtration. The signaling activities of this cytokine are thus constrained both by its association with TTR and by its short half-life in the circulation. The complete spectrum of physiologic situations in which plasma RBP concentration exceeds that of TTR remains to be clarified, but it has been reported that blood level of RBP is elevated in obese mice and humans (12) . Under these circumstances, the elevated RBP/TTR ratio in plasma results in marked activation of STRA6 and STAT3/5 and, consequently, in insulin resistance (5, 10) . Notably, a large body of epidemiologic studies indicates that obesity is a risk factor for multiple types of cancers, including colon and breast cancers (28, 29) . The association is particularly strong with colorectal cancer where convincing evidence identified obesity to be a cause for the disease (30) . Breast and colorectal cancers are also associated with insulin resistance. For example, high levels of fasting insulin have been associated with a 2-to 3-fold increase in risk of mortality from breast cancer (31) . The molecular mechanisms that underlie the association between excess body weight and insulin resistance and cancer are incompletely understood, but accumulated evidence suggests that the adipose tissue is an important mediator of this link (32) . Among adipocyte-derived factors that have been implicated in involvement in cancer development, the most extensively studied is leptin whose expression is upregulated in obese animals and which displays distinct protumorigenic activities (28, (33) (34) (35) . The findings of the present work suggest that holo-RBP/STRA6 signaling may comprise another important molecular mechanism through which obesity promotes cancer development.
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